Business
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a nove
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"image","alt":"Tarsus Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Tarsus Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":218,"url":"https://media.zenfs.com/en/globenewswire.com/4482918fc3608261626e37d219861c79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cQm2WplrrloWGnMrMCklYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNQ--/https://media.zenfs.com/en/globenewswire.com/4482918fc3608261626e37d219861c79","width":300,"height":218}},"lazy":false},{"type":"text","content":"Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year","length":120,"tagName":"p"},{"type":"text","content":"Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion","length":128,"tagName":"p"},{"type":"text","content":"Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation","length":197,"tagName":"p"},{"type":"text","content":"Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027","length":180,"tagName":"p"},{"type":"text","content":"Management to host conference call today, May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET","length":90,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the first quarter ended March 31, 2026.","length":176,"tagName":"p"},{"type":"text","content":"“XDEMVY is driving a fundamental shift in how Demodex blepharitis is diagnosed and treated,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “As we look across the business, every key signal is gaining momentum, and we are seeing the market expand as a result – reinforcing XDEMVY’s expected growth trajectory toward potential peak sales exceeding $2 billion. Equally as exciting, XDEMVY validates a repeatable playbook for category creation. We are now scaling that approach across our pipeline, with several catalysts ahead that we believe will drive the next phase of gr...